Infinity Net Income Per Employee Trend from 2010 to 2021

Infinity Pharmaceuti Net Income Per Employee is decreasing over the last several years with slightly volatile swings. Net Income Per Employee is predicted to flatten to -1,894,321. During the period from 2010 to 2021 Infinity Pharmaceuti Net Income Per Employee regressed destribution of quarterly values had coefficient of variationof(77.47) and r-squared of  0.65. Infinity Pharmaceuti Revenues is most likely to decrease significantly in the upcoming years. The last year's value of Revenues was reported at 1.72 Million. The current Research and Development Expense is estimated to increase to about 27.5 M, while Consolidated Income is projected to decrease to (43.7 M).

Infinity Historical Trends 

 
Refresh
Check Infinity Pharmaceuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Infinity main balance sheet or income statement drivers, such as Gross Profit of 1.8 M, Interest Expense of 2.3 M or Operating Expenses of 63.4 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.27, PPandE Turnover of 0.91 or Receivables Turnover of 761. Infinity financial statements analysis is a perfect complement when working with Infinity Pharmaceuti Valuation or Volatility modules. It can also supplement various Infinity Pharmaceuti Technical models. Check out Risk vs Return Analysis.

Infinity Net Income Per Employee Breakdown

Showing smoothed Net Income Per Employee of Infinity Pharmaceuti with missing and latest data points interpolated. Infinity Pharmaceuti's Net Income Per Employee historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Infinity Pharmaceuti's overall financial position and show how it may be relating to other accounts over time.
Net Income Per Employee10 Years Trend
Decreasing
Slightly volatile
 Net Income Per Employee 
Share
      Timeline 

Infinity Net Income Per Employee Regression Statistics

Arithmetic Mean(951,054)
Geometric Mean 647,810
Coefficient Of Variation(77.47)
Mean Deviation 663,928
Median(578,270)
Standard Deviation 736,771
Range 1,812,051
R-Value(0.81)
R-Squared 0.65
Significance 0.001514
Slope(164,884)

Infinity Net Income Per Employee History

2011-210.7 K
2012-349.5 K
2013-704.3 K
2014-89.3 K
2015-578.3 K
2016-1.3 M
2017-1.9 M
2018-450.1 K
2019-1.9 M
2020-1.8 M
2021-1.9 M

Be your own money manager

Our tools can tell you how much better you can do entering a position in Infinity Pharmaceuti without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Idea Optimizer Now

   

Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Infinity Pharmaceuti using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Check out Risk vs Return Analysis. Note that the Infinity Pharmaceuti information on this page should be used as a complementary analysis to other Infinity Pharmaceuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Tools for Infinity Stock

When running Infinity Pharmaceuti price analysis, check to measure Infinity Pharmaceuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infinity Pharmaceuti is operating at the current time. Most of Infinity Pharmaceuti's value examination focuses on studying past and present price action to predict the probability of Infinity Pharmaceuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Infinity Pharmaceuti's price. Additionally, you may evaluate how the addition of Infinity Pharmaceuti to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go